Medicilon in one place
Dive Deeper
Corporate News
- Corporate News
Medicilon Highlights at the 2025 CBA-China Conference
- Corporate News
Medicilon Supports BIOTIME in Securing Dual China-US Approvals for CDC7 Inhibitor BIOT-006
- Corporate News
BIK Therapeutics and Medicilon Sign Strategic Collaboration Agreement to Accelerate Oncology Drug Innovation.
- Corporate News
Medicilon Passes FDA Inspection, Reinforcing Global R&D Excellence
- Corporate News
Empowering Innovation in Regenerative Medicine: Medicilon’s ELU42 IND Team Wins Eluciderm’s “Excellent Service Award”
- Corporate News
Medicilon Celebrates Nanolattix Group’s T320 ADC Drug Approval in China, the US, and Australia
Medicilon Academy
- Medicilon Academy
PDX-Derived Organoids: How This Mini-Tumor Transforming Cancer Research?
- Medicilon Academy
Large Animal Models: Essential Tools in Disease Research
- Medicilon Academy
PDXO Model: A Significant Advancement in Precision Oncology
- Medicilon Academy
Did You Know That Medicilon Can Handle DMPK Studies?
- Medicilon Academy
Medicilon’s GLP-1 New Drug R&D Service
- Medicilon Academy
Antibody-oligonucleotide conjugates (AOCs) —A new wave of drug conjugates
Digital Materials
- Digital Materials
Boston Innovation Meets ADME Precision
- Digital Materials
Medicilon—Developing PDX-Derived Organoid Models for Efficacy Evaluation of Anticancer Therapies (Download)
- Digital Materials
Medicilon DMPK & Bioanalysis Services (Download)
- Digital Materials
Medicilon—High Quality Integrated Drug R&D Services (Download)
- Digital Materials
